Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001927528 | SCV002158817 | uncertain significance | not provided | 2022-10-05 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with RMND1-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The serine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 1395019). This variant is present in population databases (rs374223733, gnomAD 0.002%). This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 63 of the RMND1 protein (p.Asn63Ser). |
Fulgent Genetics, |
RCV002490163 | SCV002778318 | uncertain significance | Combined oxidative phosphorylation defect type 11 | 2021-08-12 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001927528 | SCV005408035 | uncertain significance | not provided | 2023-06-15 | criteria provided, single submitter | clinical testing | BP4, PM2_moderate |